和铂医药(上海)有限责任公司(简称“和铂医药”)再获一笔重磅交易。6月23日,和铂医药发布公告称,公司与日本制药巨头大冢制药株式会社(简称“大冢制药”)达成全球战略合作,将其自主研发的、治疗自身免疫性疾病的BCMA×CD3双特异性T细胞衔接器(TCE)HBM7020授权给大冢制药,交易总金额达6.7亿美元。 年内第二笔跨国BD交易 本次交易是和铂医药今年以来的第二笔跨国BD交易(通过引进授权、...
Source Link和铂医药(上海)有限责任公司(简称“和铂医药”)再获一笔重磅交易。6月23日,和铂医药发布公告称,公司与日本制药巨头大冢制药株式会社(简称“大冢制药”)达成全球战略合作,将其自主研发的、治疗自身免疫性疾病的BCMA×CD3双特异性T细胞衔接器(TCE)HBM7020授权给大冢制药,交易总金额达6.7亿美元。 年内第二笔跨国BD交易 本次交易是和铂医药今年以来的第二笔跨国BD交易(通过引进授权、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.